• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Campbell Appoints Carrie Anderson Chief Financial Officer

    1/25/23 4:30:00 PM ET
    $CPB
    $EMBC
    $IART
    Packaged Foods
    Consumer Staples
    Medical/Dental Instruments
    Health Care
    Get the next $CPB alert in real time by email

    Campbell Soup Company (NYSE:CPB) today announced the appointment of Carrie L. Anderson as Executive Vice President and Chief Financial Officer, effective Feb. 6.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230125005725/en/

    Carrie Anderson (Photo: Business Wire)

    Carrie Anderson (Photo: Business Wire)

    Anderson will lead Campbell's finance function, including controllership, corporate financial planning and analysis, corporate strategy and development, tax, treasury, internal audit, investor relations, transactional services and financial systems. She will report to Campbell's President and Chief Executive Officer Mark Clouse and become a member of the company's Operating Committee and a Corporate Officer. Anderson succeeds Mick Beekhuizen, who was appointed President of Campbell's Meals & Beverages division in November 2022.

    "I am delighted to welcome Carrie to our leadership team. She brings a wide range of diverse, strategic experience and financial discipline, and her expertise in capital management and deployment will help us continue to drive our growth plans and enhance our performance," said Clouse. "Her collaborative approach combined with a track record of driving transformation, delivering results and developing strong finance teams will be invaluable as we continue to build momentum in the business."

    Anderson brings a wealth of financial experience working in a variety of complex industries, as well as a background in manufacturing and engineering. She joins Campbell from Integra LifeSciences (NASDAQ:IART), a leading global medical technology company, where she has served as Executive Vice President and Chief Financial Officer since 2019. Before Integra, Anderson spent seven years with Dover Corporation in several leadership roles, including Chief Accounting Officer/Corporate Controller, and Vice President and CFO for the company's engineered systems and printing and identification businesses. Previously, Anderson spent six years as Vice President and Chief Financial Officer of Delphi Product & Service Solutions, a division of Delphi Corporation. While at Delphi, she also held leadership positions in finance, treasury and investor relations. Anderson started her career with General Motors.

    Anderson earned her B.S. in chemical engineering from Purdue University and an MBA from Ball State University. She serves on the board of directors of Embecta Corp. (NASDAQ:EMBC) and is a member of its Audit and Nominating & Governance committees.

    About Campbell Soup Company

    For more than 150 years, Campbell (NYSE:CPB) has been connecting people through food they love. Generations of consumers have trusted Campbell to provide delicious and affordable food and beverages. Headquartered in Camden, N.J. since 1869, Campbell generated fiscal 2022 net sales of nearly $8.6 billion. Our portfolio includes iconic brands such as Campbell's, Cape Cod, Goldfish, Kettle Brand, Lance, Late July, Milano, Pace, Pacific Foods, Pepperidge Farm, Prego, Snyder's of Hanover, Swanson and V8. Campbell has a heritage of giving back and acting as a good steward of the environment. The company is a member of the Standard & Poor's 500 as well as the FTSE4Good and Bloomberg Gender-Equality Indices. For more information, visit www.campbellsoupcompany.com or follow company news on Twitter via @CampbellSoupCo.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230125005725/en/

    Get the next $CPB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CPB
    $EMBC
    $IART

    CompanyDatePrice TargetRatingAnalyst
    The Campbell's Company
    $CPB
    4/23/2025$36.00Sell
    UBS
    Embecta Corp.
    $EMBC
    4/10/2025$15.00Neutral
    Mizuho
    Integra LifeSciences Holdings Corporation
    $IART
    3/31/2025Hold → Buy
    Argus
    The Campbell's Company
    $CPB
    3/17/2025Overweight → Equal Weight
    Consumer Edge Research
    The Campbell's Company
    $CPB
    3/6/2025$48.00 → $37.00Overweight → Neutral
    Analyst
    Integra LifeSciences Holdings Corporation
    $IART
    12/2/2024$25.00 → $20.00Underweight
    Morgan Stanley
    Embecta Corp.
    $EMBC
    12/2/2024$13.00 → $20.00Underweight → Equal-Weight
    Morgan Stanley
    Embecta Corp.
    $EMBC
    11/27/2024$26.00Neutral → Buy
    BTIG Research
    More analyst ratings

    $CPB
    $EMBC
    $IART
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Integra LifeSciences Holdings Corporation

      SC 13G - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)

      11/12/24 5:20:30 PM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Integra LifeSciences Holdings Corporation

      SC 13G/A - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)

      11/12/24 12:54:20 PM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Embecta Corp.

      SC 13G/A - Embecta Corp. (0001872789) (Subject)

      11/8/24 10:57:43 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care

    $CPB
    $EMBC
    $IART
    Leadership Updates

    Live Leadership Updates

    See more
    • The Campbell's Company Appoints Senior Leaders to Accelerate Growth

      Elizabeth Duggan Named President Snacks Division Janda Lukin Named Chief Growth Officer The Campbell's Company (NASDAQ:CPB) today announced senior management changes to accelerate progress against its strategic plan and drive continued growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250415591360/en/Elizabeth Duggan Elizabeth Duggan, currently Senior Vice President and General Manager, Campbell's Company of Canada, has been appointed President of the company's Snacks division, effective May 12, 2025. Janda Lukin, currently Senior Vice President and Chief Marketing Officer, Snacks, has been named to the newly created ro

      4/15/25 4:00:00 PM ET
      $CPB
      Packaged Foods
      Consumer Staples
    • Campbell's Names Aaron Gwinner Chief Digital & Technology Officer

      The Campbell's Company (NASDAQ:CPB) (Campbell's) today announced the appointment of Aaron Gwinner as Senior Vice President and Chief Digital & Technology Officer, effective April 14, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250403934949/en/Aaron Gwinner Gwinner will lead Campbell's digital transformation strategy and leverage innovative technologies to enhance the company's agility, strengthen capabilities and accelerate growth. He will be responsible for the overall strategy and execution of the company's digital and information technology (IT) function. He will report to Dan Poland, Campbell's Executive Vice Preside

      4/3/25 4:30:00 PM ET
      $CPB
      Packaged Foods
      Consumer Staples
    • PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

      Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca

      3/11/25 7:05:00 AM ET
      $BAX
      $BMRN
      $EMBC
      $HSIC
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical Specialities

    $CPB
    $EMBC
    $IART
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Embecta Corp. Reports Second Quarter Fiscal 2025 Financial Results

      PARSIPPANY, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta" or the "Company") (NASDAQ:EMBC), a global diabetes care company, today reported financial results for the three and six month periods ended March 31, 2025. "This quarter's financial results were once again slightly ahead of our prior expectations, as our teams executed well, which included driving an acceleration in our free-cash flow generation, thereby allowing us to continue to repay debt and create additional balance sheet flexibility," said Devdatt (Dev) Kurdikar, President and Chief Executive Officer of embecta. Mr. Kurdikar added, "In this challenging operating environment, we are raising key profitability

      5/9/25 6:30:00 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • embecta Announces Quarterly Cash Dividend

      PARSIPPANY, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. ("embecta") (NASDAQ:EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on June 13, 2025 to stockholders of record at the close of business on May 28, 2025. About embectaembecta is a global diabetes care company that is leveraging its 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on

      5/9/25 6:00:00 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Integra LifeSciences Reports First Quarter 2025 Financial Results

      PRINCETON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2025. First Quarter 2025 Highlights First quarter revenues of $382.7 million increased 3.7% on a reported basis and decreased 3.5% on an organic basis compared to the prior year. First quarter GAAP earnings per diluted share of $(0.33), compared to $(0.04) in the prior year; adjusted earnings per diluted share of $0.41, compared to $0.55 in the prior year.Reaffirming full-year 2025 revenue guidance range and updating adjusted EPS guidance to account for the impact

      5/5/25 6:30:00 AM ET
      $IART
      Medical/Dental Instruments
      Health Care

    $CPB
    $EMBC
    $IART
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Integra LifeSciences Holdings Corporation

      SCHEDULE 13G - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)

      5/9/25 2:16:33 PM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Embecta Corp.

      10-Q - Embecta Corp. (0001872789) (Filer)

      5/9/25 11:45:56 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Embecta Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Embecta Corp. (0001872789) (Filer)

      5/9/25 6:56:44 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care

    $CPB
    $EMBC
    $IART
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Melcher David F bought $177,646 worth of shares (13,000 units at $13.67), increasing direct ownership by 20% to 76,681 units (SEC Form 4)

      4 - Embecta Corp. (0001872789) (Issuer)

      2/25/25 4:26:16 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Essig Stuart bought $1,499,979 worth of shares (52,641 units at $28.49), increasing direct ownership by 12% to 487,922 units (SEC Form 4)

      4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

      5/24/24 4:08:19 PM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • Hill Barbara B bought $995,816 worth of shares (36,350 units at $27.40) (SEC Form 4)

      4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

      5/22/24 4:09:18 PM ET
      $IART
      Medical/Dental Instruments
      Health Care

    $CPB
    $EMBC
    $IART
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • UBS initiated coverage on Campbell Soup with a new price target

      UBS initiated coverage of Campbell Soup with a rating of Sell and set a new price target of $36.00

      4/23/25 8:15:09 AM ET
      $CPB
      Packaged Foods
      Consumer Staples
    • Mizuho initiated coverage on Embecta Corp. with a new price target

      Mizuho initiated coverage of Embecta Corp. with a rating of Neutral and set a new price target of $15.00

      4/10/25 12:41:09 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Integra upgraded by Argus

      Argus upgraded Integra from Hold to Buy

      3/31/25 8:28:08 AM ET
      $IART
      Medical/Dental Instruments
      Health Care

    $CPB
    $EMBC
    $IART
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP and CFO Elguicze Jacob covered exercise/tax liability with 4,948 shares, decreasing direct ownership by 3% to 168,599 units (SEC Form 4)

      4 - Embecta Corp. (0001872789) (Issuer)

      4/8/25 4:25:00 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • SVP, Global Manuf./Sup. Chain Curtis Shaun covered exercise/tax liability with 3,249 shares, decreasing direct ownership by 5% to 59,061 units (SEC Form 4)

      4 - Embecta Corp. (0001872789) (Issuer)

      4/8/25 4:22:22 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • SVP, GC, Head Corp. Dev., Secy Mann Jeffrey Z covered exercise/tax liability with 5,285 shares, decreasing direct ownership by 4% to 139,439 units (SEC Form 4)

      4 - Embecta Corp. (0001872789) (Issuer)

      4/8/25 4:20:11 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care

    $CPB
    $EMBC
    $IART
    Financials

    Live finance-specific insights

    See more
    • Embecta Corp. Reports Second Quarter Fiscal 2025 Financial Results

      PARSIPPANY, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta" or the "Company") (NASDAQ:EMBC), a global diabetes care company, today reported financial results for the three and six month periods ended March 31, 2025. "This quarter's financial results were once again slightly ahead of our prior expectations, as our teams executed well, which included driving an acceleration in our free-cash flow generation, thereby allowing us to continue to repay debt and create additional balance sheet flexibility," said Devdatt (Dev) Kurdikar, President and Chief Executive Officer of embecta. Mr. Kurdikar added, "In this challenging operating environment, we are raising key profitability

      5/9/25 6:30:00 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • embecta Announces Quarterly Cash Dividend

      PARSIPPANY, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. ("embecta") (NASDAQ:EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on June 13, 2025 to stockholders of record at the close of business on May 28, 2025. About embectaembecta is a global diabetes care company that is leveraging its 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on

      5/9/25 6:00:00 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Integra LifeSciences Reports First Quarter 2025 Financial Results

      PRINCETON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2025. First Quarter 2025 Highlights First quarter revenues of $382.7 million increased 3.7% on a reported basis and decreased 3.5% on an organic basis compared to the prior year. First quarter GAAP earnings per diluted share of $(0.33), compared to $(0.04) in the prior year; adjusted earnings per diluted share of $0.41, compared to $0.55 in the prior year.Reaffirming full-year 2025 revenue guidance range and updating adjusted EPS guidance to account for the impact

      5/5/25 6:30:00 AM ET
      $IART
      Medical/Dental Instruments
      Health Care